10/16/06 HyperLaw, Inc.®




HyperLaw Amicus Curiae Brief October 16, 1996


Zyban uk online buy

"Back to DOJ Antitrust Review of Thomson/West Merger Page"

UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLUMBIA
_______________________________________

UNITED STATES OF AMERICA, ET AL, Docket No. CA 96-1415 (PLF)

Plaintiffs, HYPERLAW'S
AMICUS CURIAE
vs. BRIEF (CORRECTED)


THE THOMSON CORPORATION, ET AL,

Defendants.
_______________________________________

A. THE POSTURE OF THE CASE BEFORE THIS COURT

Shortly after the Government filed its antitrust complaint in June 1996, defendants Thomson Corporation and West Publishing Company consummated their merger. The defendants have already proceeded to combine the operations of the companies. Some of defendants' facilities have been consolidated, and others have been closed. In addition, some products have already been terminated.1

The Government has proposed a settlement of the claims it asserted in the June 1996 antitrust complaint. If the consent decree is allowed, Defendants will avoid a trial, avoid disclosure of documents and avoid an examination of the facts.

Having already avoided any significant disclosure, Defendants now seek to rush the Court in its review of this matter—purportedly due to losses being suffered. However, because the merger has effectively already occurred, the defendants are prejudiced (by what they characterize as "delay" in this proceeding) only to the extent that they are inhibited in their ability to discontinue operations, discontinue some products and increase prices on other products. (The Government did not seek to stay the consummation of the merger, and the parties proceeded with the merger knowing that this review by the Court would be necessary.) Therefore, the posture of this case before the Court is like that in any other non-merger related consent decree submitted to the Court for consideration pursuant to the Tunney Act. The Court should not feel rushed by a situation Defendants knowingly created, and it should proceed with its statutorily mandated review—to:

1. Assure compliance with the letter of the Tunney Act2;

2. Determine whether the proposed consent decree provides adequate relief to address the points raised in the complaint; and

3. Determine whether the proposed consent decree is in the public interest.3

The Court has three primary options at this juncture; it may:

1. Refuse to approve the proposed consent decree, which would result in one of two outcomes:

a. the Government would have to litigate in an effort to protect the public from anticompetitive effects of the merger; or

b. the parties would have to propose modifications that would then meet with the approval of the Court.

2. Require substantive changes—or changes to provide a level of clarity presently absent from the proposed decree. (For example, the proposed license agreement either permits copying of text of court opinions from West case reporters, or it does not. The proposed license agreement should, at the very least, be clear about this issue).

3. Delay approving the consent decree until the Government meets its Tunney Act obligations. (As described in HyperLaw's October 10, 1996 letter to Mr. Conrath, the Tunney Act is a "sunshine law" and, in addition, serves to establish a level of accountability for the Government's actions. If the Government wishes to promote a license agreement which for many older opinions will provide licensees with the meaningless right to star-paginate blank pages, then it should step up and articulate this position; and then attempt to defend its position before this Court and before the public. In the future, the proponents of this position should not be able to excuse their conduct—accountability for the Government's decisions must be assigned.) The Court has already demonstrated, by shedding a little light on the "no-contest provision" of the license agreement, that there could be immediate 'evaporation' of this dubious provision. Similarly, shedding light on other provisions of the consent decree, by sheer embarrassment alone, may well cause the parties to offer up other previously non-negotiable provisions.

Finally, HyperLaw notes the irony of the fact that both the DOJ and the defendants take the position that the proposed license agreement (which is part of the proposed consent decree) should not be scrutinized by the Court—because, they maintain, it really does not relate to the complaint, and it was something that the Government could have never obtained in litigation...clearly Catch-22.

B. HYPERLAW'S REQUESTS TO THE COURT

First, HyperLaw has asked the Court to assure that the specific statutory requirements of the Tunney Act be met. HyperLaw's letter to DOJ dated October 10, 1996 (HyperLaw Exhibit J) sets forth the several ways in which the Act's requirements have not been met. This is not a matter of discretion for either the DOJ or this Court. Just one example of why the Court must insist that these requirements are met can be seen in the statutory requirement that documents central to the DOJ's consideration of this matter be disclosed.4 This mandates disclosure of specific, critical, industry-controlling documents reviewed by the DOJ. It is clear that the merger/consent decree/proposed license package will severely exacerbate an already highly controlled industry and assist the cartel which has control. The secret 1988 agreements between West and Lexis, the documents which reflect how and where those control agreements have been administered (and subsequent modifications) are a sine qua non to even the most basic understanding of the effects of the proposed consent decree.5

Second, the Court must find an answer to the question of why the license agreement is part of the relief presented to this Court for its review and approval. HyperLaw wonders whether the Government continues to even suggest that it strong-armed the defendants into the license agreement. It is clear that this was not the case. HyperLaw submits that the license agreement is part of the consent decree for the following reasons:

(1) While negotiating the consent decree, the Government was insisting upon divestitures of companies and products which were not acceptable to Thomson and West (This is the import of contemporaneous newspaper articles6, although only an examination of the Government and the defendants would permit this to be proven directly.) The voluminous comments from varied sources have criticized the inadequacies of the divestitures, as compared to the allegations of the complaint.7 The Government further refuses to share the most basic information regarding the divestitures, including the HHI of both divested and non-divested products, as well as the breakdown on sales of the vaunted 51 divested products. If the divested products are inadequate, then one must look elsewhere for balancing relief—presumably this was the intended purpose of the proposed license. Clearly there is linkage between the limited and ineffectual divestitures and the competitive relief that could be provided by an effective license agreement.

(2) Clearly the merger directly enhances the market effect of West's claims to rights in the citation and text of court opinions and statutes. The merger of West's market power in these areas with the enormous market power of Thomson in secondary source material without question has a major impact on competition.8 The Government misreads the comments of Matthew Bender, HyperLaw, Geronimo Development Company, the State of New Mexico, and others by stating dismissively:

We disagree with TA's oft-repeated conclusion that West's control over access to some judicial opinions and statutes is a "consequence" of the merger of Thomson and West. Mem. at 5. Simply, whatever role West has relating to access to judicial opinions is a pre-condition to the merger and not caused by it.

See Plaintiffs' Opposition to Tax Analysts' Motion For Reconsideration Of Its Denial of Amicus Curiae Status, October 15, 1996, at 4. Matthew Bender correctly notes that the consequence of the merger is to extend the West-Lexis' copyright pool to the other major publisher, Thomson, to the exclusion of smaller publishers. The appended 1994 advertisement shows just the types of integrated products that Lawyers Cooperative Publishing offered, which will now tie into this pool.9 Anyone competing with the products shown in that advertisement (and the unfortunate purchasers of the divested products) now must face the West copyright factor. The Government is not correct in its assertion that those objecting to the insufficiency of the consent decree seek to remedy preexisting anticompetitive effects.

The Court must also require the Government to respond specifically to criticism of the consent decree and license agreement made in the Comment Letters—and to the filings in this proceeding. For example, HyperLaw, in its September 30, 1996 motion to this court, pointed out the impropriety of the Government's relying upon documents not filed in this Court and not made available to the public in construing the license agreement. HyperLaw referred specifically to this statement:

11. On page 44 of its responses to comments, the government states:

(1) The plaintiffs interpret the proposed license to mean that a license must be issued for star pagination any set of cases selected by the licensee, even if West or any other person had previously selected a similar set of cases. (2) Defendants have stated to plaintiffs that they would not consider a CD-ROM product which included exactly the same cases included in a West print reporter to be an infringement. (3) Indeed, Matthew Bender has introduced such a product and we are informed defendants have not challenged it as a "selection" infringement. (4) Defendants would object to a print reporter which simply replicated a West print reporter ... (numeration of sentences added).

How has the Government responded to HyperLaw's clear objection? No response.

It is possible that in the future (in a closed, private arbitration in Minnesota) a competitor might try to introduce the entire record of this proceeding in an attempt to persuade the arbitrator that these vague assertions of the Government are somehow binding on West-Thomson. This will not be necessary if the license agreement itself can be read clearly. If anything, the Court, in its order relating to the consent decree, should provide the needed specificity.

Similarly, the agreement does not state what it does not cover (e.g., the text of the opinions). Once again, one could introduce the entire proceedings herein to a committee of Congress considering something akin to a database protection bill—to counter the expected Thomson-West argument that there was a compulsory license in effect. The easier solution is for the Court to mandate clarity now.

Moreover, the Government has provided no documentation whatsoever to demonstrate the reasonableness of the license rate—and, indeed, its position seems to be that anything is better than nothing. First, this is nonsense, but more important is the fact that this will allow Thomson-West to state that the rate has been "approved by the Government" as 'standardized royalty rates which the Antitrust Division approved as commercially reasonable' ) as described by HyperLaw at page 5 of its September 3, 1996 comments to the Government. See HyperLaw Exhibit N-4. Again the DOJ evaded the question. (The Government could have stated that: "The Government has not approved the rates as commercially reasonable, nor did it conduct a study as to the competitive impact of the rates on a variety of products in a variety of media." Instead, the Government's response was that it is not responsible for what Thomson-West does right under its nose—or for what vagueness allow Thomson-West to assert in the future.)

C. CONSEQUENCES OF THE COURT NOT PRESSING THE PARTIES

The Government was aware of the fact that the next largest legal publisher, Lexis, had entered into the secret 1988 cross-licensing agreements with West—agreements which created the copyright equivalent of a clandestine "patent pool"—giving Lexis access to the West citations and text to both case law and statutes, and (it appears) vice versa.10 It does not appear that the government understood the significance of this fact—and it may be too embarrassed to now step forward and comment on the state of the emperor's attire. The merger has the undeniable result of significantly expanding this copyright cartel to include the other large legal publisher, Thomson. The result is that, in the post-merger period, West, Thomson, and Lexis will be able to use the intellectual property pool to the exclusion of all other legal publishers. The cost of this to the public is staggering. It makes effective on-line legal research for poor and middle class litigants a joke—not to mention the effect of this cartel on new technologies such as CD-ROM and Internet.11 Well into the 21st Century the entire country will pay an override—nothing less that a monopoly tax to the very few who own the text of and citation to the case law prior to 1991.

The proposed license agreement may have been well-intentioned, but it is a completely insufficient attempt to provide to other legal publishers access to this copyright pool. It is insufficient in the industry, insufficient under the Tunney Act, and is even insufficient to address the specific problems addressed in the government's own complaint. Once again, the insufficiencies of the proposed license agreement would be demonstrated were the Government to make available to the Court the 1988 settlement agreements between West and Lexis—as well as the documents explaining where those agreements have been and how they have been modified.12 In its October 10, 1996 letter to Mr. Conrath at the DOJ, HyperLaw described the many references to these 1988 agreements made in connection to the proposed consent decree—and provided an analysis of the probable contents of these agreements.13 For the reasons set forth in the unsealing motion papers that HyperLaw sought to file in the United States District Court, District of Minnesota, it is in the public interest that the Court require these 1988 agreements to be made public. (HyperLaw did not file this motion because, incredibly, West advised HyperLaw that the agreements are not in the possession of the Minnesota court that apparently still supervises the operation of the major industry players under these agreements.14 Further, the docket sheets in these matters do not reflect that the agreements were ever actually filed with the Court.15)

D. CONCLUSION

The Government and the defendants join together to argue that the Microsoft decision substantially curtails the Court's discretion. The Government goes well beyond the Microsoft decision by engaging in narrow interpretations of the complaint that the Government drafted. In other words, the Government is proposing a new principle: where the relief does not address the allegations in the complaint, just reinterpret the complaint.16

This is a true win-win situation for Thomson-West. The complaint, however, has res judicata/collateral estoppel effect on the Government, and the standard is not how the Government construes the complaint, but rather what future antitrust enforcement activity will be forestalled by the complaint before the Court.17

The time is now, and the place is this Court. If these agreements and the industry control cannot be examined by Your Honor, the public will pay the monopoly tax long into the future—and an already highly anti-competitive industry will become virtually closed. This may indeed be the last opportunity to, at least, examine the facts—given the enormous political power amassed by this merger.

DATED: October 17, 1996

RESPECTFULLY SUBMITTED,

/S/

______________________________________

Lorence L. Kessler (D.C. Bar # 203521)

Counsel for HyperLaw, Inc.

Suite 400

1825 I Street, N.W.

Washington, D.C. 20006

202-857-8067

OF COUNSEL:

Carl J. Hartmann, III

New York, NY

Paul J. Ruskin

Douglaston, NY

PREVIOUS EXHIBITS FILED BY HYPERLAW

Exhibit 1 Opinion dated August 5, 1996, Matthew Bender & Company and HyperLaw v. West.

Exhibit 2 Excerpt from Docket Sheet, West Publishing Company v. Mead Data Central, Inc., 4-85-931, United States District Court, District of Minnesota.

Exhibit 3 Article, How West Was Won, American Lawyer, September, 1996.

HyperLaw Exhibit A HyperLaw Motion For Summary Judgment, Matthew Bender & Company Inc. and HyperLaw v. West Publishing Company.

HyperLaw Exhibit B- Letters, from HyperLaw to Attorney General Reno and Lawrence Fullerton dated September 26, 1996 re amicus brief.

EXHIBITS FILED AS A BINDER WITH THIS BRIEF

HyperLaw Exhibit C Affidavit of Kendall F. Svengallis dated October 7, 1996.

HyperLaw Exhibit D Advertisement, "Only a select few can discuss the specifics of a case with each other", Lawyers Cooperative Publishing Advertisement, Law Technology Product News, September 1994.

HyperLaw Exhibit E Complaint, Mead Data Central, Inc. v. West Publishing Company, 76-Civ. 3618 W.C.C., United States District Court, Southern District of New York, August 16, 1976 (Antitrust including FLITE and JURIS and spurious copyright claims to text of court opinions.)

HyperLaw Exhibit F Complaint, Mead Data Central, Inc. v. West Publishing Company, C-3-87-426, United States District Court, Southern District of Ohio, August 18, 1987. (Antitrust including control of statutes and opinions, FLITE and JURIS, Fifth and Eleventh Circuits, spurious copyright claims to text of court opinions.)

HyperLaw Exhibit G Docket Sheet, West Publishing Company v. Mead Data Central, Inc., 4-85-931, United States District Court, District of Minnesota.

HyperLaw Exhibit H Docket Sheet, West Publishing Company v. Mead Corporation, Mead Data Central, Inc., Civ. 4-88-142, United States District Court, District of Minnesota.

HyperLaw Exhibit I Complaint, West Publishing Company v. Mead Corporation, Mead Data Central, Inc., Civ. 4-88-142, United States District Court, District of Minnesota, February 22, 1988. (Antitrust relating to Lexis exclusive access to regulatory material and copyright infringement for copying from West reporters.)

HyperLaw Exhibit J Letter, dated October 10, 1996, from Carl J. Hartmann, counsel for HyperLaw, to Craig Conrath, Esq. re disclosure of documents.

HyperLaw Exhibit K Letter, dated March 13, 1995, from Carl J. Hartmann to Joseph Musilek, counsel for West, confirming, inter alia, that a copy of the 1988 settlement agreements were not in the possession of the Minnesota United States District Court supervising the settlement.

HyperLaw Exhibit L Draft Motion to Intervene in Minnesota United States District Court, re unsealing by HyperLaw describing facts surrounding the 1988 settlement agreements.

HyperLaw Exhibit M Letter Dated October 3, 1996 from Joel I. Klein, Deputy Assistant Attorney General to Alan D. Sugarman declining to file an amicus brief in Matthew Bender and HyperLaw v. West in support of HyperLaw's motion for a determination that West copyrights are not infringed when a competing publisher keys-in and publishes the text of court opinions from a West case reporter, but does not key-in the West headnotes and syllabi.

HyperLaw Exhibit N HyperLaw Comment Letters Filed Under the Tunney Act with United States Department of Justice, N-1 June 26, 1996 to Assistant Attorney General Anne Bingaman (not in comment letters filed by DOJ), N-2 June 26, 1996 to Craig Conrath, N-3 June 28, 1996 to Craig Conrath, N-4 September 3, 1996 to Craig Conrath.

HyperLaw Exhibit M Tax Analysts' Memorandum in Support of Motion For Reconsideration of Leave to Participate As Amicus Curiae

AMENDED CERTIFICATE OF SERVICE

I hereby certify that on October 15, 1996 I caused copies of HyperLaw Exhibits to its Amicus Curiae Brief to be served by Federal Express for delivery on October 16, 1996, and have confirmed that delivery upon the following.

Craig W. Conrath, Esq.

U.S. Department of Justice

Antitrust Division

Merger Task Force

1401 H Street N.W.

Washington, D.C. 20005

Wayne D. Collins, Esq.

Attorney for The Thomson Corporation

Shearman & Sterling

Citicorp Center

New York, New York 10022

Gary L. Reback, Esq.

Wilson Sonsini

650 Page Mill Road

Palo Alto, CA 94304

I hereby certify that prior to 4:00 PM on October 16, 1996 I caused copies of HyperLaw's Amicus Curiae Brief to be sent by Facsimile upon the following, and have re-served the corrected version of the brief on all parties by facsimile on October 17, 1996.

Craig W. Conrath, Esq.

U.S. Department of Justice

Antitrust Division Merger Task Force

1401 H Street N.W.

Washington, D.C. 20005

Facsimile: (202) 307-5802

James E. Schatz, Esq.

Schatz Paquin Lockridge

Grindal & Holstein P.L.L.P.

Suite 2200

100 Washington Avenue

So.Minneapolis, MN 55401

Facsimile: (612) 339-0981

Attorney General of New York

Steven D. Houck, Esq.

Chief Antitrust Bureau

120 Broadway, Suite 2601

New York, NY 10271

Attorney General of Illinois

Christine H. Rosso

Chief, Antitrust Bureau

100 Randolph St.

12th Floor

Chicago, IL 60601

Facsimile: (312) 814 2549

Attorney General of Connecticut

Aaron S. Bayer

Deputy Attorney General

110 Sherman Street

Hartford, Connecticut 06105

Facsimile: (860) 566-1704

George K. Weber

Assistant Attorney General

Chief, Consumer Protection

and Antitrust Division

One Ashburton Place

Boston, MA 02109

Facsimile: (617) 727-5765

Kevin J. O'Connor

Attorney General of Wisconsin

Assistant Attorney General

123 West Washington Ave.

Madison, Wisconsin 53717

Facsimile: (608) 267-2223

Wayne D. Collins, Esq.

Shearman & Sterling

Citicorp Center

New York, New York 10022

Facsimile: (212) 848-7170

Gary E. Reback, Esq.

Wilson Sonsini Goodrich & Rosati

650 Page Mill Road

Palo Alto, California 94304

Facsimile: (415) 493-6811

Is bupropion a generic



Bupropion rezeptfrei kaufen. "It is not, of course, the case that every patient will benefit from psilocybin in one or another circumstance. However, it's also not the case that every single patient can benefit from psilocybin at any one time, and it seems pretty clear that for most people, the drug is not going to increase their chances of surviving." He said the results of study would be published in a forthcoming issue of the journal Brain Stimulation — a publication of the British Library Science. A 'positive' mood, as long it's 'safe' In the study, researchers scanned brains of 40 healthy volunteers before and after taking either psilocybin or a placebo, combination of psilocybin and a placebo. Participants completed the Neuropsychological Testing Battery, a test that measured their mental flexibility and mood in response to stressful situations. They were also asked to complete the Beck Depression Inventory, a test that measures mood as a way to assess how depression and other mental problems impact one's ability to cope. There were 10 volunteers in each group that received psilocybin and 10 who the placebo. Half had no prior history of mental issues, were not clinically depressed, and taking medication for their problems. The scientists noted that when they studied the groups, found some differences between the groups — namely, that people who had not previously a mental health problem and had used cannabis before the study were likely to take the drug. However, once people took placebo, there were no differences between those who were treated with psilocybin and the four participants who received placebo. Overall, those in the psilocybin group showed significantly increased brain activation in regions related to the regulation of emotions, increased creativity, Accutane generics brands and the formation of new memories, researchers said. In terms of a negative reaction, the researchers observed "a significant reduction in neurophysiological anxiety" — an effect that is "consistent with an 'overheated' state of mind" that may make the drug appear unpleasant, they said. So does it happen? The researchers said they believe that, contrary to some earlier findings, "some people do respond in a positive manner" to psilocybin. They said that further study is needed on this effect — and they hope that, eventually, this sort of knowledge will help guide clinical decisions. "What's going to be important is examine if psilocybin really does have the power to give you a very specific 'be happy, be brave' moment," D'Souza said. "We hope to start studying what 'be happy, be brave' is going to lead and also how we can be better at designing studies that will lead to sort of experience." D'Souza Adapalene cost uk added that scientists remain a step behind conventional medicine in terms of understanding how people respond to.

  1. Cessnock
  2. Bupropion Port Hedland
  3. Perth
  4. Bupropion Lismore
  5. Ballarat


Bupropion 150mg $124.69 - $1.04 Per pill
Bupropion 150mg $178.69 - $0.99 Per pill
Bupropion 150mg $259.7 - $0.96 Per pill
Bupropion 150mg $340.7 - $0.95 Per pill
Bupropion 150mg $97.68 - $1.09 Per pill



Bupropion is used for treating depression.

Phenergan sleep uk | Where can i buy tretinoin cream


WilmingtonGreshamLanham SeabrookWest Bend
ArmstrongFernieEast KootenayToowoomba
Bupropion RichmondNowraIpswichBupropion Gympie


Cost of generic bupropion -$10) or by getting free insurance with a doctor's prescription. For $16 pill, I have had no side effects. That's less than 20% of my monthly cost. I'd gladly pay that much if I was getting a drug really needed as regular part of my health care, but instead have a pill that is essentially "cheap." I guess that's where my frustration comes from. The fact that all my efforts to be better with my health have been for nothing doesn't give me hope that there Bupropion 150mg $70.68 - $1.18 Per pill is some greater good. As someone who's been in this long, I think that my point is if there is, I've already died. The pharmaceutical industry, which for years has been trying to make a profit the detriment of patients, is now so entrenched in making sure it gets the most people, there's little motivation to try and make something better Dapoxetine online pharmacy that we can afford and something bupropion rezeptfrei kaufen that people actually need. There's lots of good research that shows people don't pay for prescription medications the way that other medical procedures do, and there's also some evidence that suggests people in the middle class pay just as much (if not more) for prescription drugs as people in less affluent areas. So I guess you have to wonder why, before I get off this train of thought, there is such a fear of taking prescription drugs that the only way to go is buy them on the black market. Perhaps someday there may be a legal way for best drugstore bb cream us people in those areas to actually get the real stuff, but until then, I'm stuck in the "there go little guys" mode. Buy clomid online uk And if it wasn't for the good people at Erowid, I'd also be a little pissed off. If you find it's still not enough, consider signing up to support the site and get even more information on how not to die. Your continued support has already helped keep this website going and there are many, many more ways to support the work that Erowid, our writers, and ourselves are doing. Please take a moment to go over these steps: www.ebrowid.org www.ebrowid.org/donate www.ebrowid.org/buy-pillstore-dollars www.ebrowid.org/get-free-insurance-with-a-doctor www.ebrowid.org/get-help-from-the-doctor www.ebrowid.org/get-support-from-your-bank www.ebrowid.org/find-help-online www.ebrowid.org/get-free-health-insurance-in-my-state The U.S. is being hit by a "vast, systematic and expensive" international conspiracy to create a global oligarchy dominated by single, group of billionaires, a new report by the America Foundation has warned.



Is Bupropion A Generic
5-5 stars based on 321 reviews

< Pantozol online apotheke :: Over the counter similar to clomid >

Assistant Attorney General

900 Fourth Avenue

Suite 2000

Seattle, WA 98164

Facsimile: (206) 587-5636

Attorney General of California

Kathleen E. Foote

Deputy Attorney General

1300 I Street

Sacramento, CA 95814

Facsimile: (916) 445-5340

/S/

___________________________________

Carl J. Hartmann

_______________________________

[1] See Exhibit 15 to Lexis-Nexis' Memorandum in Support of Motion to Intervene, dated September 11, 1996.

Viagra buy n